Russia’s Federal Medical Biological Agency (FMBA) has announced a new colon cancer vaccine at the Eastern Economic Forum in Vladivostok. Preclinical trials show strong results, including major tumour shrinkage and improved survival. The vaccine is awaiting regulatory approval.

BulletsIn

• Colon cancer vaccine developed by FMBA, Russia
• Announced at 10th Eastern Economic Forum, Vladivostok
• Target: colorectal cancer, major global health burden
• Trials showed 60–80% tumour reduction
• Slowed disease progression in test subjects
• Higher survival rates, no adverse effects reported
• Vaccine works by activating immune system against tumour
• Classified as therapeutic, not preventive
• Pending regulatory approval before clinical rollout
• FMBA also testing vaccines for glioblastoma, melanoma